Rokote

Rokote Laboratories Finland Ltd. Launches a Nasal Spray Vaccine for COVID-19 Using Gene Transfer Technology. The vaccine utilizes a safe adenovirus vector containing cloned DNA strands, which enables nasopharyngeal cells to produce viral proteins and generate an immune response. The actual SARS-CoV-2 virus is not present in the vaccine. Preliminary results indicate that the vaccine performed well in animal studies. This nasal spray COVID-19 vaccine is based on gene transfer technology developed by a research team from the University of Eastern Finland, which has been successfully applied in multiple clinical trials for gene therapy treating cardiovascular diseases and cancer. It employs a safe adenovirus vector with cloned DNA strands, allowing nasopharyngeal cells to produce viral proteins and trigger a vaccine response.